Key Developments in Ovarian Cancer and Adjusting to COVID-19

Physicians are adapting to new treatment protocols and a different workload as the Covid 19 pandemic continues. On the 22nd of September SurvivorNet will hold a collaborative conversation with opinion leaders in the field to talk new approvals and the new normal.

This session qualifies for CME credit. Click here to claim CME credit.

Talking Points:

Updates
We’ll be discussing new announcements from ESMO, as well as recent approvals and trials pertaining to ovarian cancer treatment that physicians should be aware of. These may well include presentations at the most recent ASCO conference about olaparib, and trials such as the SOLO 2 trial, currently ongoing clinical trials with margetuximab for ovarian cancer, and the recent disappointing negative trial regarding using immunotherapy to treat ovarian cancer.

Racial Disparities
African Americans have a lower survival rate of ovarian cancer than other racial groups, and this seems to be a socio economic issue, not a genetic one. A big thing physicians can do to help this disparity is to undergo implicit bias training at their clinic. It’s a subject that often people don’t want to talk about, but is important to address.

Mental Health
Physicians have had to adjust to a lot over the last few months. Hospital budgets are being slashed, funding for clinical trials and research is going away, workloads are increasing and changing….it’s a very unsettling time. Doctors suffer disproportionately from burnout and depression at the best of times, but now, anecdotally, more than ever. Our panel will give advice to colleagues on how to cope with this.

Disclosures Declaration

• Thomas J Herzog, MD
  Consulting: AZ, Caris, Clovis, Genentech, GSK, Merck
• Elizabeth Jewell, MD
  Other Financial Support: Summitt Biomedical Imaging
• Rebecca Arend, MD
  No Disclosures
• Dana Chase, MD
  Speakers Bureau: Astra Zeneca, GSK/TESARO, Clovis, Merck
  Consultant: Astra Zeneca, GSK/TESARO, Clovis, Merck
• Staff at SurvivorNet and CME Outfitters have no financial relationships to disclose